A Phase 2 interventional study of Pemetrexed and Carboplatin in Breast Cancer, sponsored by Eli Lilly and Company. Completed at 22 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-20.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing pemetrexed in Breast Neoplasms — none open to participants now, none under way, none of them phase 3. Pemetrexed · Breast Neoplasms.
Among the 14 studies testing pemetrexed in Breast Neoplasms, this one is the 2nd largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2006, is one of 10 in phase 2, and was the 10th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →None of the 14 studies testing pemetrexed in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 13
First in 2003; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 135 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 50 across the 13 interventional studies. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 5 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
88 studies in Breast Neoplasms by Eli Lilly and Company: 7 open now, 22 under way, 8 of them phase 3. Of 61 finished, 40 (66%) have results posted.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 41st largest by enrollment of the 80 interventional ones that give a count, is one of 5 that started in 2006, is one of 41 in phase 2, and was the 30th registered.
Eli Lilly and Company’s Breast Neoplasms studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing pemetrexed in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 88 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to help answer the following research questions:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pemetrexed 600 mg/m\^2 was administered intravenously over approximately 10 minutes on Day 1. Carboplatin was given over approximately 30 minutes on Day 1 beginning after the end of the Pemetrexed infusion, consistent with a target of AUC (Area under the plasma drug concentration versus time curve) 5.0 mg\*min/mL. The cycle of treatment was 21 days.
Drug: Pemetrexed · Drug: Carboplatin
Vinorelbine 30 mg/m\^2 was given over approximately 6-10 minutes on Day 1 and Day 8. Gemcitabine 1200 mg/m\^2 was given over approximately 30 minutes on Day 1 and Day 8 beginning after the end of the Vinorelbine infusion. The cycle of treatment was 21 days.
Drug: Gemcitabine · Drug: Vinorelbine
600 mg/m\^2, administered intravenously (IV) every 21 days until disease progression or unacceptable toxicity.
Also known as: LY231514, Alimta
AUC 5 mg\*min/mL, administered IV every 21 days until disease progression or unacceptable toxicity.
1200 mg/m\^2 gemcitabine, administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
Also known as: LY188011, Gemzar
30 mg/m\^2 vinorelbine administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
Tumor Response Rate
Participants with best overall response determined from complete response (CR) or partial response (PR) according to Response Criteria in Solid Tumors (RECIST) criteria. For CR or PR, best response must be confirmed. A second assessment performed at 28 days. Two determinations of CR before progression required for rate to=CR. Evaluations include: CR=Disappearance of lesions. PR=≥30% size decrease of lesions. Progressive Disease (PD)=≥20% size increase of lesions. Stable Disease (SD)=Not enough shrinkage for PR nor enough increase for PD. Overall Response Rate=PR+CR/Qualified Participants\*100.
Time frame: Baseline up to 30 days of follow-up after 21 cycles of treatment
Duration of Response (DOR)
DOR-RECIST criteria of (Complete Response \[CR =Disappearance of lesions\] or Partial Response \[PR=≥30% size decrease of lesions\]) is defined as time from the date when measurement criteria are met for CR or PR until the date of first observation of progressive disease (PD) or death from study disease. For participants who die from causes other than study disease and without PD, DOR will be censored at the date of death. For participants who have not died as of the data cut-off date who are without PD, DOR was censored at last contact date.
Time frame: Time of response to progressive disease (up to 19 months)
Time to Progressive Disease (PD)
Time to PD is defined as the time from the date of study enrollment to the first documented date of PD or death from study disease. For participants who die from causes other than study disease and without PD, time to PD was censored at the date of death. For participants not known to have died as of the data cut-off date and do not have PD, time to PD was censored at the last contact date. For participants who received subsequent chemotherapy (after discontinuation from the study chemotherapy) prior to disease progression, time to PD was censored at the date of subsequent chemotherapy.
Time frame: Baseline to measured PD (up to 25.1 months)
Time To Treatment Failure (TTTF)
TTTF is defined as the time from date of study enrollment to the first documented date of death, PD, or study treatment discontinuation due to adverse event (AE). For participants not known to have discontinued as of the data cut-off date, TTTF is censored at the last contact date. For participants who discontinued for reasons other than death, PD, or AE, TTTF is censored at the date of discontinuation.
Time frame: Baseline to end of treatment (up to 21.9 months)
Time to Response
Time to response (Complete Response(CR) or Partial Response (PR) is defined as the time from the date of study enrollment to the first date when the measurement criteria are met for complete response or partial response (whichever status is recorded first). CR=Disappearance of target lesions lesions. PR=≥30% size decrease of lesions.
Time frame: Baseline to response (up to 7.8 months)
Number of Participants With Adverse Events (AE)
A listing of adverse events is presented in the Reported Adverse Event Module.
Time frame: every cycle up to twenty-one 21-day cycles (plus 30 days of follow-up)
| Milestone | Pemetrexed/Carboplatin | Gemcitabine/Vinorelbine |
|---|---|---|
| Started | 69 | 66 |
| Received at least 1 dose of study drug | 65 | 66 |
| Completed | 0 | 0 |
| Not completed | 69 | 66 |
| Withdrew: Adverse event | 10 | 7 |
| Withdrew: Death due to study disease | 1 | 0 |
| Withdrew: Entry criteria not met | 1 | 2 |
| Withdrew: Subject decision | 6 | 8 |
| Withdrew: Physician decision | 17 | 12 |
| Withdrew: Progressive disease | 34 | 37 |
Participants with best overall response determined from complete response (CR) or partial response (PR) according to Response Criteria in Solid Tumors (RECIST) criteria. For CR or PR, best response must be confirmed. A second assessment performed at 28 days. Two determinations of CR before progression required for rate to=CR. Evaluations include: CR=Disappearance of lesions. PR=≥30% size decrease of lesions. Progressive Disease (PD)=≥20% size increase of lesions. Stable Disease (SD)=Not enough shrinkage for PR nor enough increase for PD. Overall Response Rate=PR+CR/Qualified Participants\*100.
| percentage of participants | Pemetrexed/Carboplatin | Gemcitabine/Vinorelbine |
|---|---|---|
| Overall Response | 26.6 (16.3 to 39.1) | 29.5 (18.5 to 42.6) |
| Complete Response | 0.0 (0.0 to 5.6) | 3.3 (0.4 to 11.3) |
| Partial Response | 26.6 (16.3 to 39.1) | 26.2 (15.8 to 39.1) |
| Stable Disease | 35.9 (24.3 to 48.9) | 34.4 (22.7 to 47.7) |
| Progressive Disease | 26.6 (16.3 to 39.1) | 27.9 (17.1 to 40.8) |
| Unknown | 10.9 (4.5 to 21.2) | 8.2 (2.7 to 18.1) |
DOR-RECIST criteria of (Complete Response \[CR =Disappearance of lesions\] or Partial Response \[PR=≥30% size decrease of lesions\]) is defined as time from the date when measurement criteria are met for CR or PR until the date of first observation of progressive disease (PD) or death from study disease. For participants who die from causes other than study disease and without PD, DOR will be censored at the date of death. For participants who have not died as of the data cut-off date who are without PD, DOR was censored at last contact date.
| Months | Pemetrexed/Carboplatin | Gemcitabine/Vinorelbine |
|---|---|---|
| Duration of Response (DOR) | 7.7 (4.2 to 12.2) | 7.5 (4.9 to 8.3) |
Time to PD is defined as the time from the date of study enrollment to the first documented date of PD or death from study disease. For participants who die from causes other than study disease and without PD, time to PD was censored at the date of death. For participants not known to have died as of the data cut-off date and do not have PD, time to PD was censored at the last contact date. For participants who received subsequent chemotherapy (after discontinuation from the study chemotherapy) prior to disease progression, time to PD was censored at the date of subsequent chemotherapy.
| Months | Pemetrexed/Carboplatin | Gemcitabine/Vinorelbine |
|---|---|---|
| Time to Progressive Disease (PD) | 5.1 (4.1 to 8.0) | 5.6 (4.2 to 7.5) |
TTTF is defined as the time from date of study enrollment to the first documented date of death, PD, or study treatment discontinuation due to adverse event (AE). For participants not known to have discontinued as of the data cut-off date, TTTF is censored at the last contact date. For participants who discontinued for reasons other than death, PD, or AE, TTTF is censored at the date of discontinuation.
| Months | Pemetrexed/Carboplatin | Gemcitabine/Vinorelbine |
|---|---|---|
| Time To Treatment Failure (TTTF) | 4.8 (3.3 to 7.0) | 5.1 (3.5 to 6.3) |
Time to response (Complete Response(CR) or Partial Response (PR) is defined as the time from the date of study enrollment to the first date when the measurement criteria are met for complete response or partial response (whichever status is recorded first). CR=Disappearance of target lesions lesions. PR=≥30% size decrease of lesions.
| Months | Pemetrexed/Carboplatin | Gemcitabine/Vinorelbine |
|---|---|---|
| Time to Response | 1.8 (1.6 to 3.3) | 1.8 (1.6 to 3.1) |
A listing of adverse events is presented in the Reported Adverse Event Module.
| participants | Pemetrexed/Carboplatin | Gemcitabine/Vinorelbine |
|---|---|---|
| Adverse Events | 64 | 66 |
| Serious Adverse Events | 18 | 22 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed/Carboplatin | — | 18/65 (27.7%) | 64/65 (98.5%) |
| Gemcitabine/Vinorelbine | — | 22/66 (33.3%) | 66/66 (100%) |
| Event | Pemetrexed/Carboplatin | Gemcitabine/Vinorelbine |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 6/65 | 0/66 |
| AnaemiaBlood and lymphatic system disorders | 5/65 | 1/66 |
| NeutropeniaBlood and lymphatic system disorders | 4/65 | 2/66 |
| VomitingGastrointestinal disorders | 3/65 | 1/66 |
| PyrexiaGeneral disorders | 2/65 | 3/66 |
| PneumoniaInfections and infestations | 2/65 | 0/66 |
| HypokalaemiaMetabolism and nutrition disorders | 2/65 | 0/66 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/65 | 2/66 |
| NauseaGastrointestinal disorders | 1/65 | 0/66 |
| Performance status decreasedGeneral disorders | 1/65 | 0/66 |
| Event | Pemetrexed/Carboplatin | Gemcitabine/Vinorelbine |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 37/65 | 51/66 |
| LeukopeniaBlood and lymphatic system disorders | 28/65 | 35/66 |
| AnaemiaBlood and lymphatic system disorders | 32/65 | 28/66 |
| NauseaGastrointestinal disorders | 31/65 | 23/66 |
| ConstipationGastrointestinal disorders | 18/65 | 26/66 |
| FatigueGeneral disorders | 23/65 | 26/66 |
| PyrexiaGeneral disorders | 5/65 | 21/66 |
| Alanine aminotransferase increasedInvestigations | 11/65 | 21/66 |
| ThrombocytopeniaBlood and lymphatic system disorders | 17/65 | 11/66 |
| Aspartate aminotransferase increasedInvestigations | 9/65 | 17/66 |
| Age Continuous(years) | Pemetrexed/Carboplatin | Gemcitabine/Vinorelbine | Total |
|---|---|---|---|
| Mean | 51.9 ± 11.38 | 52.3 ± 10.40 | 52.1 ± 10.87 |
| Sex: Female, Male(Participants) | Pemetrexed/Carboplatin | Gemcitabine/Vinorelbine | Total |
|---|---|---|---|
| Female | 69 | 66 | 135 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Pemetrexed/Carboplatin | Gemcitabine/Vinorelbine | Total |
|---|---|---|---|
| Caucasian | 67 | 61 | 128 |
| African | 1 | 3 | 4 |
| Hispanic | 0 | 1 | 1 |
| East Asian | 1 | 0 | 1 |
| West Asian | 0 | 1 | 1 |
| Region of Enrollment(participants) | Pemetrexed/Carboplatin | Gemcitabine/Vinorelbine | Total |
|---|---|---|---|
| Spain | 18 | 18 | 36 |
| Switzerland | 5 | 4 | 9 |
| Israel | 9 | 9 | 18 |
| Germany | 9 | 12 | 21 |
| Italy | 16 | 14 | 30 |
| Turkey | 5 | 3 | 8 |
| South Africa | 7 | 6 | 13 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Pemetrexed/Carboplatin | Gemcitabine/Vinorelbine | Total |
|---|---|---|---|
| ECOG 0 | 39 | 39 | 78 |
| ECOG 1 | 28 | 27 | 55 |
| ECOG 2 | 2 | 0 | 2 |
| Hormonal Receptor Status(participants) | Pemetrexed/Carboplatin | Gemcitabine/Vinorelbine | Total |
|---|---|---|---|
| Estrogen and Progesterone Negative | 19 | 21 | 40 |
| Estrogen and/or Progesterone Positive | 49 | 44 | 93 |
| Unknown | 1 | 1 | 2 |
| Human Epidermal Growth Factor Receptor 2 (HER-2/Neu)(participants) | Pemetrexed/Carboplatin | Gemcitabine/Vinorelbine | Total |
|---|---|---|---|
| Positive | 12 | 13 | 25 |
| Negative | 53 | 49 | 102 |
| Not Performed | 0 | 1 | 1 |
| Unknown | 4 | 3 | 7 |
| Tumor Differentiation Grade(participants) | Pemetrexed/Carboplatin | Gemcitabine/Vinorelbine | Total |
|---|---|---|---|
| Grade I | 6 | 3 | 9 |
| Grade II | 25 | 27 | 52 |
| Grade III | 32 | 30 | 62 |
| Unknown | 6 | 6 | 12 |
1 further baseline measures are reported on the registry.
The record gives a start of Jun 2006, a primary completion of Apr 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Carboplatin